Recent treatment patterns and survival outcomes in pancreatic cancer according to clinical stage based on single-center large-cohort data
- Authors
- Lee, Doo-Ho; Jang, Jin-Young; Kang, Jae Seung; Kim, Jae Ri; Han, Youngmin; Kim, Eunjung; Kwon, Wooil; Kim, Sun-Whe
- Issue Date
- Nov-2018
- Publisher
- The Korean Association of Hepato-Biliary-Pancreatic Surgery
- Keywords
- Neoadjuvant therapy; Survival rate; Pancreas neoplasms
- Citation
- Ann Hepatobiliary Pancreat Surg. , v.22, no.4, pp.386 - 396
- Journal Title
- Ann Hepatobiliary Pancreat Surg.
- Volume
- 22
- Number
- 4
- Start Page
- 386
- End Page
- 396
- URI
- https://scholarworks.bwise.kr/gachon/handle/2020.sw.gachon/80442
- DOI
- 10.14701/ahbps.2018.22.4.386
- ISSN
- 2508-5778
- Abstract
- Backgrounds/Aims
We performed a retrospective, single-center cohort study to evaluate the impact of various treatment modalities and recent changes in treatment modalities, including the increased application of chemotherapy, on survival in patients with pancreatic cancer.
Methods
All patients with pancreatic cancer who were diagnosed and treated at Seoul National University Hospital between January 2007 and December 2014 were registered in a prospective clinical database and included in this retrospective study. All patients' radiologic imaging diagnoses were re-reviewed according to the National Cancer Center Network guidelines. The patients were divided into four groups according to their clinical stage, and each clinical stage group was further divided into four groups according to treatment modality.
Results
Overall, 475 (28.9%) patients had resectable pancreatic cancer, 129 (7.8%) patients borderline resectable pancreatic cancer, 384 (23.3%) patients locally advanced pancreatic cancer, and 658 (40.0%) patients metastatic pancreatic cancer. Among the patients with borderline resectable pancreatic cancer, the median survival was significantly longer in the neoadjuvant therapy (NAT)+surgery groups (24 months) than the surgery without NAT (16 months) group (p=0.049). A multivariate survival analysis revealed that compared with the surgery group, the 5-year mortality risk was decreased by 35% in the NAT+surgery group (24 vs. 20 months, p=0.045).
Conclusions
This retrospective cohort study showed that the rates of resectable and surgically treatable pancreatic cancer were 29.1% and 32.2%, which are higher than those reported previously, and aggressive NAT for select advanced-stage patients could lead to better survival outcomes.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 의과대학 > 의학과 > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.